Skip to main content
. 2022 Feb 17;14(4):1028. doi: 10.3390/cancers14041028
Abbreviation Meaning Abbreviation Meaning
5-FU 5-fluorouracil mAbs monoclonal antibodies
ACT adoptive cell therapies MAIT mucosal-associated invariant T
ADCC antibody-dependent cell-mediated cytotoxicity MANAs mutation-associated neoantigens
APCs antigen-presenting cells mCRC metastatic CRC
bsAbs bispecific antibodies MDSCs myeloid-derived suppressor cells
bsTCEs T cell-engaging bsAbs miRNA microRNA
CAAs cancer-associated antigens MMR mismatch repair
CAR-T cell chimeric antigen receptor T cell MSI microsatellite instable
CEA carcinoembryonic antigen MSI-H MSI-high
cGAS cyclic GMP-AMP synthase MSS microsatellite stable
CIMP CpG island methylator phenotype Nbs nanobodies
CIN chromosomal instability NDV Newcastle disease virus
CRC colorectal cancer NK natural killer
ctDNA circulating tumor DNA NKG2 Natural Killer Group 2
CTLA-4 cytotoxic T-lymphocyte-associated protein 4 NLR neutrophil-to-lymphocyte
DCs dendritic cells NSCLC non-small-cell lung cancer
dMMR MMR deficiency PD-1 programmed cell death protein 1
DR5 death receptor 5 PD-L1 programmed cell death ligand 1
dsDNA double stranded DNA PFS progression-free survival
EpCAM/CD326 epithelial cell adhesion molecule pMMR proficient MMR
EphA2 ephrin type-A receptor 2 PtdSer phosphatidyl serine
FLT3L Flt-3 Ligand SNPs single-nucleotide polymorphisms
Gal-9 galectin-9 STING stimulator of interferon genes
GUCY2C guanylyl cyclase C STRs short tandem repeats
HAVCR2 hepatitis A virus cellular receptor 2 T regs regulatory T cells
HLA human leukocyte antigen TAAs tumor-associated antigens
HMGB1 high mobility group box 1 protein TAG tumor-associated glycoprotein
ICB immune checkpoint blockade TAMs tumor-associated macrophages
IFNs interferons TCR T cell receptor
ILs interleukins TGFβR2 transforming growth factor β receptor type 2
IMiDs immunomodulatory drugs TIL tumor-infiltrating lymphocyte
IT immunotherapy TIM-3 T cell immunoglobulin- and mucin-domain-containing-3
LAG-3 lymphocyte activation gene-3 TMB-H high tumor mutational burden
lncRNA long non-coding RNA TME tumor microenvironment